Tirzepatide 60mg

Dual GIP/GLP-1 Receptor Agonist for Metabolic Research

Tirzepatide 60mg is a groundbreaking dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for advanced metabolic and obesity research. This generous 60mg supply provides researchers with ample material for comprehensive studies in glucose regulation, weight management, and metabolic health.

Why Researchers Choose Tirzepatide 60mg:

• Dual Mechanism Innovation: First-in-class dual GIP/GLP-1 receptor agonist for studying synergistic metabolic effects
• Superior Potency: Enhanced efficacy compared to single-receptor agonists in preclinical models
• Generous 60mg Supply: Substantial quantity ideal for extended research protocols and multiple experimental runs
• Weight Management Research: Investigate mechanisms of appetite suppression and energy expenditure
• Glucose Homeostasis: Explore insulin secretion, glucagon suppression, and glycemic control pathways
• Cost-Effective: Larger format provides exceptional value for comprehensive research programs
• Research-Grade Purity: Pharmaceutical-quality peptide (≥98%) for reliable outcomes

Ideal Research Applications:

Perfect for laboratories investigating metabolic disorders, obesity mechanisms, diabetes pathophysiology, and incretin biology. Tirzepatide's unique dual-agonist profile makes it invaluable for researchers exploring:

• Dual incretin receptor activation and synergistic effects
• Body weight regulation and adipose tissue metabolism
• Glucose-dependent insulin secretion mechanisms
• Appetite regulation and satiety signaling pathways
• Cardiovascular benefits of metabolic interventions
• Beta-cell function and pancreatic health
• Lipid metabolism and hepatic steatosis
• Energy expenditure and thermogenesis

Technical Specifications:

• Quantity: 60mg (substantial research supply)
• Type: Dual GIP/GLP-1 receptor agonist
• Structure: 39 amino acid synthetic peptide
• Form: Lyophilized powder for reconstitution
• Purity: ≥98% (HPLC verified)
• Molecular Weight: ~4813 Da
• Storage: Store at 2-8°C before reconstitution; -20°C after reconstitution
• Solubility: Reconstitute with bacteriostatic water
• Stability: Enhanced stability profile with C20 fatty acid modification

Research Advantages:

Tirzepatide represents a paradigm shift in incretin-based research, combining GIP and GLP-1 receptor activation to produce superior metabolic outcomes. The 60mg supply enables researchers to conduct extensive dose-response studies, long-term efficacy investigations, and comprehensive mechanistic analyses.

Unique Mechanism: Unlike single-receptor agonists, Tirzepatide activates both GIP and GLP-1 receptors, leading to enhanced insulin secretion, reduced glucagon levels, delayed gastric emptying, and significant appetite suppression. The GIP component may also contribute to improved lipid metabolism and insulin sensitivity.

Research Breakthrough: Clinical studies have demonstrated unprecedented weight loss and glycemic control with tirzepatide, making it a critical tool for understanding next-generation metabolic therapeutics and obesity treatment mechanisms.

Value Proposition: The 60mg format provides researchers with sufficient material for comprehensive research programs, eliminating the need for frequent reordering and ensuring consistency across experimental batches.

Important Disclaimer: This product is sold exclusively for research and laboratory purposes. Not intended for human consumption, therapeutic use, weight loss applications, or veterinary use. For in vitro and animal research only.

*Price per vial.
*This product is in powder form and is not reconstituted.
*For research purposes only.
*Tested at 99% purity.
*Free shipping.
*All sales final.